Short Sellers Are Betting Against This Biotech Stock at All-Time Highs, But You Should Still Add it to Your Watchlist

Exelixis (EXEL) demonstrates strong technical momentum, recently hitting a new all-time high. Shares are up more than 70% over the past 52 weeks. EXEL maintains a 100% “Buy” technical opinion from Barchart. Valuation appears stretched, with Morningst…